Catalyst Wire Dossier Catalyst Wire Dossier

MOM-M281-004 extension study (M281)

M281 · Momenta Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MOM-M281-004 extension study (M281), covering 2022-02-16 to 2022-02-16. Get the full timeline:

Most recent: Clinical Trial Update: An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis [Phase 2]

See pricing